0001335105 false 0001335105 2022-10-07 2022-10-07 0001335105 LIXT:CommonStockParValue0.0001PerShareMember 2022-10-07 2022-10-07 0001335105 LIXT:WarrantsToPurchaseCommonStockParValue0.0001PerShareMember 2022-10-07 2022-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 7, 2022

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

delaware   001-39717   20-2903526

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

680 East Colorado Boulevard, Suite 180

Pasadena, California 91101

(Address of principal executive offices)

 

(631) 830-7092

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share  

 

LIXT

 

 

The Nasdaq Stock Market LLC

Warrants to Purchase Common Stock, par value $0.0001 per share  

 

LIXTW

 

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On October 7, 2022, the Company held its annual meeting of stockholders (the “Annual Meeting”). The matters voted upon were:

 

Proposal 1: The election of seven director nominees to the Company’s Board of Directors to serve for a one-year term expiring at the 2023 annual meeting of stockholders.

 

Proposal 2: To ratify the appointment of Weinberg & Company, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.

 

Proposal 3: To approve a proposal to amend the Company’s 2020 Stock Incentive Plan (the “2020 Plan”) to increase the number of common shares issuable thereunder by 1,800,000 shares.

 

The results of the voting were as follows:

 

Proposal 1 (election of directors):

 

Each of the director nominees to the Company’s Board of Directors was elected as follows:

 

Nominee  Votes For  Votes Withheld  Broker Non-Votes
Dr. John Kovach   7,253,572    664,003    2,930,767 
Dr. Stephen Forman   7,214,029    703,546    2,930,767 
Dr. Yun Yen   7,811,544    106,031    2,930,767 
Gil N Schwartzberg   7,212,012    705,563    2,930,767 
Regina Brown   7,803,957    113,618    2,930,767 
Dr. René Bernards   7,813,148    104,427    2,930,767 
Bas van der Baan   7,809,679    107,896    2,930,767 

 

Proposal 2 (appointment of accounting firm):

 

Votes For  Votes Against  Abstain  Broker Non-Votes
10,786,234   54,345   7,763   0 

 

Proposal 3 (amendment of 2020 Plan):

 

Votes For  Votes Against  Abstain  Broker Non-Votes
7,661,488   256,087   0   2,930,767 

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 11, 2022 LIXTE BIOTECHNOLOGY HOLDINGS, INC.
  (Registrant)
     
  By: /s/ JOHN S. KOVACH
    John S. Kovach, Chief Executive Officer